Literature DB >> 17579025

CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts.

Antoni Chan1, Deng-Li Hong, Ann Atzberger, Simon Kollnberger, Andrew D Filer, Christopher D Buckley, Andrew McMichael, Tariq Enver, Paul Bowness.   

Abstract

Human NK cells are divided into CD56(bright)CD16(-) cells and CD56(dim)CD16(+) cells. We tested the hypothesis that CD56(bright) NK cells can differentiate into CD56(dim) cells by prospectively isolating and culturing each NK subset in vitro and in vivo. Our results show that CD56(bright) cells can differentiate into CD56(dim) both in vitro, in the presence of synovial fibroblasts, and in vivo, upon transfer into NOD-SCID mice. In vitro, this differentiation was inhibited by fibroblast growth factor receptor-1 Ab, demonstrating a role of the CD56 and fibroblast growth factor receptor-1 interaction in this process. Differentiated CD56(dim) cells had reduced IFN-gamma production but increased perforin expression and cytolysis of cell line K562 targets. Flow cytometric fluorescent in situ hybridization demonstrated that CD56(bright) NK cells had longer telomere length compared with CD56(dim) NK cells, implying the former are less mature. Our data support a linear differentiation model of human NK development in which immature CD56(bright) NK cells can differentiate into CD56(dim) cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579025     DOI: 10.4049/jimmunol.179.1.89

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  128 in total

1.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Suchitra Pandey; Vanessa A York; Janice Arakawa-Hoyt; Hanspeter Pircher; Philip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

Review 2.  Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity.

Authors:  Till Strowig; Fabienne Brilot; Christian Münz
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 3.  Dendritic cell interactions with NK cells from different tissues.

Authors:  Guido Ferlazzo; Christian Münz
Journal:  J Clin Immunol       Date:  2009-03-12       Impact factor: 8.317

Review 4.  CD56bright natural killer (NK) cells: an important NK cell subset.

Authors:  Aurélie Poli; Tatiana Michel; Maud Thérésine; Emmanuel Andrès; François Hentges; Jacques Zimmer
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

Review 5.  Evolution of non-cytotoxic uterine natural killer cells.

Authors:  Satyan Kalkunte; Clinton O Chichester; Francesca Gotsch; Charles L Sentman; Roberto Romero; Surendra Sharma
Journal:  Am J Reprod Immunol       Date:  2008-05       Impact factor: 3.886

Review 6.  Hidden talents of natural killers: NK cells in innate and adaptive immunity.

Authors:  Megan A Cooper; Marco Colonna; Wayne M Yokoyama
Journal:  EMBO Rep       Date:  2009-09-04       Impact factor: 8.807

Review 7.  Role of natural killer cells in HIV pathogenesis.

Authors:  Jeffrey Ward; Edward Barker
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

Review 8.  Biology and clinical effects of natural killer cells in allogeneic transplantation.

Authors:  Jonathan E Benjamin; Saar Gill; Robert S Negrin
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

9.  Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus.

Authors:  Danika Schepis; Iva Gunnarsson; Maija-Leena Eloranta; Jon Lampa; Stefan H Jacobson; Klas Kärre; Louise Berg
Journal:  Immunology       Date:  2008-06-18       Impact factor: 7.397

10.  HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells.

Authors:  Henoch S Hong; Johanna M Eberhard; Phillip Keudel; Benjamin A Bollmann; Matthias Ballmaier; Nupur Bhatnagar; Margot Zielinska-Skowronek; Reinhold E Schmidt; Dirk Meyer-Olson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.